
Chris Arendt, CSO of Takeda, likens the AI overhaul at the pharma to gutting and rebuilding an old house, from the plumbing and electrical up, while you’re still living there. In a Fireside Chat at Grand Rounds U.S. in Seattle, Arendt sat down with Editor in Chief Simone Fishburn to discuss how Takeda is integrating AI across R&D, in and beyond the science, while still executing on the active programs in drug development. View full story: https://www.biocentury.com/article/659807 #Artif...
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Ep. 119 - Blackstone's Galakatos on funding biotech's hardest mile

Ep. 118 - Regeneron's Gonçalo Abecasis on turning genetic data into drug targets

Ep. 117 - C-Path's Klaus Romero on moving genetic medicines beyond one patient

Ep. 116 - Ovid's Jeremy Levin on biotech in the balance
Free AI-powered recaps of The BioCentury Show and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.